-+ 0.00%
-+ 0.00%
-+ 0.00%

Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing

PUBT·08/25/2026 11:00:52
Listen to the news
Summit says FDA sets Nov. 14, 2026 action date for ivonescimab lung cancer filing
  • Summit Therapeutics’ BLA for ivonescimab with platinum-doublet chemotherapy entered FDA review for EGFR-mutated advanced non-squamous NSCLC.
  • PDUFA goal action date set for Nov. 14, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608250700BIZWIRE_USPR_____20260825_BW415559) on August 25, 2026, and is solely responsible for the information contained therein.